Radiation therapy in the treatment of canine and feline thymomas: a retrospective study (1985-1999)

2001 ◽  
Vol 37 (5) ◽  
pp. 489-496 ◽  
Author(s):  
AN Smith ◽  
JC Wright ◽  
Brawner WRJr ◽  
SM LaRue ◽  
L Fineman ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Retrospective Study ◽  
Survival Time ◽  
Median Survival ◽  
Stable Disease ◽  
Tumor Size ◽  
Median Survival Time ◽  
Overall Response Rate ◽  
Response Rate ◽  
Clinical Signs

A retrospective study was performed of 17 dogs and seven cats with various stages of thymoma treated with radiation alone or as an adjunctive therapy. Analysis revealed an overall response rate of 75% (15/20 evaluable cases). Partial (i.e., >50% reduction in tumor size) and complete (i.e., no detectable tumor) responses were included. Complete responses were rare (4/20). Three of five animals with stable disease (i.e., <50% change in tumor size) had improvements in clinical signs, despite lack of measurable response. A median survival time of 248 days (range, 93 to 1,657+ days) was achieved in dogs, and a median survival time of 720 days (range, 485 to 1,825+ days) was achieved in cats. Radiation therapy appears to be useful in the management of invasive thymomas in dogs and cats.

Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer.

1989 ◽  
Vol 7 (9) ◽  
pp. 1310-1317 ◽  
Author(s):  
P Preusser ◽  
H Wilke ◽  
W Achterrath ◽  
U Fink ◽  
L Lenaz ◽  
...  
Keyword(s):  
Survival Time ◽  
Median Survival ◽  
Phase Ii ◽  
Metastatic Disease ◽  
Median Survival Time ◽  
Response Rate ◽  
Response Duration ◽  
World Health ◽  
Who Grade ◽  
Median Response

In this phase II multicenter trial, 67 evaluable patients with advanced measurable gastric carcinoma were treated with a combination of etoposide, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), and cisplatin (EAP). The overall response rate was 64%, including 21% complete responses (CRs). In 55 patients with metastatic disease, 31 responses (51%) including eight CRs (15%) were achieved. Responses were seen in all metastatic sites, but the response rate was lower in patients with peritoneal carcinomatosis. In 12 patients with locoregional disease, six CRs and six partial responses (PRs) were observed. Eight CRs (three and five in patients with metastatic and locoregional disease, respectively) were pathologically confirmed. The overall median response duration was 7 months; it was 16 months for patients achieving CR (22 months for pathologically confirmed CR [pCR]), and 6 months for PR. The median survival time for all patients was 9 months, for the patients who achieved CR 17 months, for pCR 23 months, and for PR 9.5 months. Median survival time for all patients with metastatic disease was 8 months, and for locoregional disease 12.5 months. Six patients (9%) (four local, two metastatic disease) were alive at 2 years, and four patients are alive and disease free at 35+ to 56+ months. Main toxicities were leukopenia and thrombocytopenia, with 64% of patients developing grade 3 to 4 myelosuppression and 12% severe infections. Nonhematologic toxicities of World Health Organization (WHO) grade 4 were not observed.

Resection, biopsy, and survival in malignant glial neoplasms

1993 ◽  
Vol 78 (5) ◽  
pp. 767-775 ◽  
Author(s):  
Bertrand C. Devaux ◽  
Judith R. O'Fallon ◽  
Patrick J. Kelly
Keyword(s):  
Radiation Therapy ◽  
Survival Time ◽  
Median Survival ◽  
Median Survival Time ◽  
Tumor Resection ◽  
External Beam Radiation ◽  
Newly Diagnosed ◽  
Content Type ◽  
Grade Iii ◽  
Fine Print

✓ Between July, 1984, and October, 1988, 263 patients (163 male, 100 female), aged from 4 to 83 years (mean 52 years), with malignant brain gliomas underwent surgical procedures: stereotactic biopsy in 160 and resection in 103 patients. There were 170 grade IV astrocytomas, 17 grade IV mixed oligoastrocytomas, 44 grade III astrocytomas, 22 grade III mixed oligoastrocytomas, and 10 malignant oligodendrogliomas. Overall median survival time was 30.1 weeks for grade IV gliomas, 87.7 weeks for grade III gliomas, and 171.3 weeks for malignant oligodendrogliomas. Multivariate analysis in 218 newly diagnosed cases revealed that the variables most strongly correlated with survival time were: tumor grade, patient age, seizures as a first symptom, a Karnofsky Performance Scale score of less than 70%, tumor resection, and a radiation therapy dose greater than 50 Gy. The proportions of patients receiving tumor resection versus biopsy in each of these prognosis factor groups were similar. Since most of the 22 patients with midline and brain-stem tumors were treated with biopsy alone, these were excluded. Considering 196 newly diagnosed patients with cortical and subcortical tumors, grade IV glioma patients undergoing resection of the contrast-enhancing mass (as evidenced on computerized tomography and magnetic resonance imaging) and postoperative external beam radiation therapy lived longer than those undergoing biopsy only and radiation therapy (median survival time 50.6 weeks and 33.0 weeks, respectively; Smirnov test, p = 0.0380). However, survival in patients with resected grade III gliomas was no better than in those with biopsied grade III lesions (p = 0.746). The authors conclude that, in selected grade IV gliomas, resection of the contrast-enhancing mass followed by radiation therapy is associated with longer survival times than radiation therapy after biopsy alone.

Treatment of metastatic breast cancer in premenopausal women using CAF with or without oophorectomy: an Eastern Cooperative Oncology Group Study.

1987 ◽  
Vol 5 (6) ◽  
pp. 881-889 ◽  
Author(s):  
G Falkson ◽  
R S Gelman ◽  
D C Tormey ◽  
C I Falkson ◽  
J M Wolter ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Survival Time ◽  
Median Survival ◽  
Median Survival Time ◽  
Response Rate ◽  
Metastatic Breast ◽  
Premenopausal Women ◽  
Prior Chemotherapy ◽  
Er Positive

One hundred thirty-one premenopausal women with metastatic breast cancer who had received no prior systemic treatment for metastases were entered on study. Patients without prior chemotherapy with estrogen receptor (ER)-positive and ER-unknown disease were randomized to receive cyclophosphamide, Adriamycin (Adria Laboratories, Columbus, OH), and 5-fluorouracil (CAF) or surgical oophorectomy followed directly by CAF (O + CAF). ER-negative patients without prior chemotherapy were directly assigned to treatment with CAF. Among randomized patients 83% have responded, and 37% have achieved a complete remission. Among ER-negative patients the complete response rate was 38%, and the complete plus partial response rate was 70%. Characteristics significantly associated with a longer time to treatment failure were age 45 or over, one or two organ sites, and performance status O. The median survival time of ER-positive patients treated with CAF is 29 months, and with O + CAF it has not yet been reached, whereas for ER-unknown patients the equivalent survival times are 41 months and 43 months respectively. For ER-negative patients treated with CAF the median survival time is 17 months. Characteristics associated with significantly longer survival among randomized patients were age 35 or over (P = .009) and only one or two organ sites involved (P = .02). Neither treatment (P = .33) nor ER status (P = .70) was significant.

scholarly journals Pituitary metastases: current practice in Japan

2015 ◽  
Vol 123 (4) ◽  
pp. 998-1007 ◽  
Author(s):  
Mika Habu ◽  
Hiroshi Tokimura ◽  
Hirofumi Hirano ◽  
Soichiro Yasuda ◽  
Yasushi Nagatomo ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Survival Time ◽  
Clinical Features ◽  
Median Survival ◽  
Median Survival Time ◽  
Cell Cancer ◽  
Optic Tract ◽  
Mass Lesion ◽  
Contributing Factors ◽  
Pituitary Metastases

OBJECT With advancement of cancer treatment and development of neuroimaging techniques, contemporary clinical pictures of pituitary metastases (PMs) must have changed from past reports. The goal of this paper was to elucidate the clinical features of PMs and current clinical practice related to those lesions. In this retrospective study, questionnaires were sent to 87 physicians who had treated PMs in Japan. RESULTS Between 1995 and 2010, 201 patients with PMs were treated by the participating physicians. The diagnosis of PM was histologically verified in 69 patients (34.3%). In the other 132 patients (65.7%), the PM was diagnosed by their physicians based on neuroimaging findings and clinical courses. The most frequent primary tumor was lung (36.8%), followed by breast (22.9%) and kidney (7.0%) cancer. The average interval between diagnosis of primary cancer and detection of PM was 2.8 ± 3.9 (SD) years. Major symptoms at diagnosis were visual disturbance in 30.3%, diabetes insipidus in 27.4%, fatigue in 25.4%, headache in 20.4%, and double vision in 17.4%. Major neuroimaging features were mass lesion in the pituitary stalk (63.3%), constriction of tumor at the diaphragmatic hiatus (44.7%), hypothalamic mass lesion (17.4%), and hyperintensity in the optic tract (11.4%). Surgical treatment was performed in 26.9% of patients, and 74.6% had radiation therapy; 80.0% of patients who underwent radiotherapy had stereotactic radiotherapy. The median survival time was 12.9 months in total. Contributing factors for good prognosis calculated by Cox proportional hazard analysis were younger age, late metastasis to the pituitary gland, smaller PM size, and radiation therapy. The Kaplan-Meier survival was significantly better in patients with breast cancer and renal cell cancer than in those with lung cancer. CONCLUSIONS At the time of this writing, approximately 60% (120/201) of PMs had been treated by stereotactic radiation therapy in Japan. The median survival time was much longer than that reported in past series. To confirm the changes of clinical features and medical practice, a prospective and population-based survey is mandatory.

Colorectal Plasmacytomas: A Retrospective Study of Nine Dogs

2006 ◽  
Vol 42 (1) ◽  
pp. 37-43 ◽  
Author(s):  
Patricia A. Kupanoff ◽  
Catherine A. Popovitch ◽  
Michael H. Goldschmidt
Keyword(s):  
Retrospective Study ◽  
Local Recurrence ◽  
Survival Time ◽  
Surgical Resection ◽  
Median Survival ◽  
Median Survival Time ◽  
Complete Excision ◽  
Complete Surgical Resection

Nine cases of colorectal plasmacytomas diagnosed between 1998 and 2001 were reviewed. Treatment consisted of complete surgical resection when possible. Two dogs had multiple plasmacytomas. Two dogs had local recurrence of the tumor at 5 and 8 months after resection. Two dogs were alive at 20 and 23 months with no recurrences at the time of follow-up. The median survival time was 15 months (range 5 to 33 months). Colorectal plasmacytomas are similar to mucocutaneous plasmacytomas, in that they tend to progress slowly and do not recur with complete excision.

Phase II Trial with Alternating Two Drug Schedules, CAP/MEC', For Advanced (Stage III Mo/Ml) Non-Small-Cell Lung Cancer

1989 ◽  
Vol 75 (5) ◽  
pp. 486-488 ◽  
Author(s):  
Diego Tummarello ◽  
Emilio Porfili ◽  
Francesco Guidi ◽  
Pierpaolo Isidori ◽  
Marzio Raspugli ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Median Survival ◽  
Stable Disease ◽  
Progressive Disease ◽  
Overall Response Rate ◽  
Response Rate ◽  
Large Cell Carcinoma ◽  
Large Cell ◽  
Drug Regimen ◽  
Improve Response Rate

Sixty-eight evaluable patients with advanced squamous cell carcinoma (48), large cell carcinoma (2) and adenocarcinoma (18) of the lung were treated with a six-drug regimen delivering two monthly alternated combinations. The combinations were cisplatin, adriamycin and cyclophosphamide (CAP) and methotrexate, etoposide and CCNU (MEC). Following a minimum of two courses, the overall response rate was 22 % (confidence limits, 12% to 32%) (15/68, 2 complete responses and 13 partial responses); 47 % (32/68) had stable disease and 31 % (21/68) had progressive disease. The responses lasted a median of 3 months (range, 1-15 months). The actuarial median survival was 11 months in responsive patients, 10 months in stable disease patients, and 5 months in progressive patients. The overall median survival obtained was 9 months (range, 2-28+ months). Toxicity was minimal, and subjective tolerance of the treatment appeared good. However, this alternating program did not improve response rate or survival.

Feline large-cell lymphoma following previous treatment for small-cell gastrointestinal lymphoma: incidence, clinical signs, clinicopathologic data, treatment of a secondary malignancy, response and survival

2018 ◽  
Vol 21 (4) ◽  
pp. 353-362
Author(s):  
Katherine Z Wright ◽  
Ann E Hohenhaus ◽  
Ariana M Verrilli ◽  
Savannah Vaughan-Wasser
Keyword(s):  
Survival Time ◽  
Median Survival ◽  
Median Survival Time ◽  
Cell Lymphoma ◽  
Clinical Signs ◽  
Large Cell ◽  
Small Cell ◽  
Event Free Survival ◽  
Free Survival ◽  
Large Cell Lymphoma

Objectives Lymphoma is a common and clinically important malignancy in cats. Development of a second malignancy has been reported previously in 7–14% of cats with small-cell gastrointestinal (GI) lymphoma. The aim of our study was to describe the incidence, clinical signs, clinicopathologic data, response to therapy and outcomes in cats diagnosed with large-cell lymphoma following treatment for small-cell GI lymphoma. Methods Medical records from a single referral specialty hospital were reviewed for all cats with lymphoma diagnosed between 2008 and 2017. The cases with a diagnosis of small-cell GI lymphoma followed by a diagnosis of any large-cell lymphoma and complete outcome data were selected for further review. Results Seven hundred and forty cats with a diagnosis of lymphoma were identified. Twelve cats (12/121) treated for small-cell GI lymphoma followed by a diagnosis of any anatomic form of large cell lymphoma were identified. Nine cats met the study inclusion criteria and were used in analyses. Mean event-free survival time from small-cell GI lymphoma diagnosis until diagnosis of large-cell lymphoma was 543 days, with a median survival time of 615 days. Mean event-free survival time from large-cell lymphoma to death was 55 days, with a median survival time of 24.5 days. Hematocrit, albumin and total protein were significantly decreased when cats developed large-cell lymphoma compared with their values at the time of small-cell lymphoma diagnosis. Conclusions and relevance Large-cell lymphoma occurred in 9.9% (12/121) of cats treated for small-cell GI lymphoma. Feline practitioners should include large-cell lymphoma on their list of differential diagnoses in cats diagnosed with small-cell GI lymphoma developing weight loss, anemia, hypoalbuminemia and hypoproteinemia.

Comparison of Survival Between Cerebellar and Supratentorial Glioblastoma Patients

Neurosurgery ◽  
2013 ◽  
Vol 73 (2) ◽  
pp. 240-246 ◽  
Author(s):  
Sunil Jeswani ◽  
Miriam Nuño ◽  
Vanessa Folkerts ◽  
Debraj Mukherjee ◽  
Keith L. Black ◽  
...  
Keyword(s):  
Multivariate Analysis ◽  
Radiation Therapy ◽  
Survival Time ◽  
Surgical Resection ◽  
Median Survival ◽  
Median Survival Time ◽  
Extent Of Resection ◽  
Tumor Location ◽  
General Belief ◽  
Cerebellar Glioblastoma

Abstract BACKGROUND: Cerebellar glioblastoma multiforme (cGBM) is rare, and although there is a general belief that these tumors have a worse prognosis than supratentorial GBM (sGBM), few studies have been published to support this belief. OBJECTIVE: To investigate the effect of cerebellar location on survival through a case-control design comparing overall survival time of cGBM and sGBM patients. METHODS: The Surveillance, Epidemiology, and End Results (SEER) registry was used to identify 132 patients with cGBM (1973-2008). Each cGBM patient was matched with an sGBM patient from among 20 848 sGBM patients on the basis of age, extent of resection, decade of diagnosis, and radiation therapy using propensity score matching. RESULTS: Within the cGBM, 37% were older than 65 years of age, 62% were men, and 87% were white. Most patients underwent surgery and radiation (74%), whereas only 26% underwent surgical resection only. The median survival time for the cGBM and sGBM matched cohort was 8 months; however, the survival distributions differed (log-rank P = .04). Survival time for cGBM vs sGBM at 2 years was 21.5% vs 8.0%, and 12.7% vs 5.3% at 3 years. Multivariate analysis of survival among cGBM patients showed that younger age (P < .0001) and having radiation therapy (P < .0001) were significantly associated with reduced hazard of mortality. Among all patients, multivariate analysis showed that tumor location (P = .03), age (P < .0001), tumor size (P = .009), radiation (P < .0001), and resection (P < .0001) were associated with survival time in the unmatched cohort. CONCLUSION: Median survival time for cGBM and sGBM patients was 8 months, but cGBM patients had a survival time advantage as the study progressed. These findings suggest that cGBM patients should be treated as aggressively as sGBM patients with surgical resection and radiation therapy.

Extraskeletal osteosarcomas in dogs: a retrospective study of 169 cases (1986-1996)

1998 ◽  
Vol 34 (2) ◽  
pp. 113-120 ◽  
Author(s):  
A Langenbach ◽  
MA Anderson ◽  
DM Dambach ◽  
KU Sorenmo ◽  
FD Shofer
Keyword(s):  
Retrospective Study ◽  
Soft Tissue ◽  
Survival Time ◽  
Cause Of Death ◽  
Median Survival ◽  
Median Survival Time ◽  
Subcutaneous Tissue ◽  
Mammary Glands ◽  
German Shepherd ◽  
Mixed Breed

Extraskeletal osteosarcomas (EOSs) are rare tumors that arise in various soft-tissue sites (e.g., gastrointestinal tract, subcutaneous tissue, spleen, liver, skin, kidney, urinary bladder, muscle, thyroid gland, eye, and mammary glands). Soft-tissue osteosarcomas (STOs) occur in older dogs with no sex predilection; beagles and rottweilers are at higher risk. Mammary gland osteosarcomas (MGOs) occur in older females; mixed-breed dogs, German shepherd dogs, and miniature poodles are at higher risk. The median survival time for cases with STO was 26 days, and the major cause of death was local recurrence (92%). The median survival time for cases with MGO was 90 days, and the major cause of death was pulmonary metastasis (62.5%).

RSR13 Plus Cranial Radiation Therapy in Patients With Brain Metastases: Comparison With the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database

2003 ◽  
Vol 21 (12) ◽  
pp. 2364-2371 ◽  
Author(s):  
Edward Shaw ◽  
Charles Scott ◽  
John Suh ◽  
Sidney Kadish ◽  
Baldassarre Stea ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Brain Metastases ◽  
Survival Time ◽  
Median Survival ◽  
Median Survival Time ◽  
Recursive Partitioning ◽  
Radiation Therapy Oncology Group ◽  
Class Ii ◽  
Recursive Partitioning Analysis ◽  
Oncology Group

Purpose: This phase II, open-label, multicenter study assessed the efficacy and safety of the potential radiation enhancer RSR13 plus cranial radiation therapy (RT) in patients with brain metastases. The primary end point was patient survival in comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database (RTOG RPA BMD). Patients and Methods: Eligibility criteria were age ≥ 18 years, Karnofsky performance score ≥ 70, and brain metastases with solid tumor histology. Patients received cranial RT, 30 Gy in 10 fractions of 3 Gy each, preceded by RSR13, 50 to 100 mg/kg intravenously over 30 minutes. Univariate and multivariate comparisons of survival and cause of death were made between class II study patients and RTOG BMD patients. Results: Fifty-seven RPA class II patients were enrolled. With a minimum follow-up of 24 months, the median survival time and 1- and 2-year survival rates were 6.4 months, 23%, and 11% for the RSR13-treated patients compared with 4.1 months, 15%, and 3% for the RTOG BMD patients (P = .0174). In an exact-matched case analysis (n = 38), median survival time for RSR13 patients was 7.3 months versus 3.4 months for the RTOG BMD patients (P = .006). There was a 54% reduction in the risk of death for RSR13 patients (P = .0267). RSR13-related adverse events of greater than or equal to grade 3 toxicity that occurred in more than one patient included hypoxia, headache, anemia, fatigue, hypertension, and intracranial hypertension. Conclusion: RSR13 plus cranial RT resulted in a significant improvement in survival, as well as a reduction in death due to brain metastases, compared with class II patients in the RTOG BMD.

Sign in / Sign up

Export Citation Format

Share Document